Completed PHASE3 INTERVENTIONAL NCT00002883

Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus

A PROSPECTIVE RANDOMISED TRIAL OF INDUCTION CHEMOTHERAPY WITH 5-FU CONTINUOUS IV INFUSION AND CISPLATIN VERSUS SURGERY IN RESECTABLE ADENOCARCINOMA OF THE LOW THIRD OF THE ESOPHAGUS AND CARDIOESOPHAGEAL JUNCTION

Sponsor: UNICANCER

Conditions Esophageal Cancer Gastric Cancer

Interventions adjuvant therapy cisplatin conventional surgery fluorouracil neoadjuvant therapy

Updated 6 times since 2017 Last updated: Feb 19, 2021 Started: Oct 31, 1996 Primary completion: Nov 30, 2006 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Esophageal Cancer and Gastric Cancer and is currently completed. UNICANCER leads this study, which shows 6 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2021 — Jul 2024 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Jan 2021 — Mar 2021 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Oct 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UNICANCER

Data source: UNICANCER

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montpellier, France